Eaton Vance Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Eaton Vance Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-225	Closed	–	–	2889
2021 Q3	$0	Buy	+225	New	+$11.2K	﹤0.01%	2739
2021 Q2	–	Sell	-125	Closed	-$6K	–	3049
2021 Q1	$6K	Buy	+125	New	+$6.66K	﹤0.01%	2548

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Centaurus Financial Anaheim, California $2.59B AUM 31.63% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Eaton Vance Management's XPH Position: Q4 2021 in Review

Eaton Vance Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2021, closing a stake of 225 shares.

Eaton Vance Management first reported a position in XPH in Q1 2021 and held it in 2 quarters. The position peaked at $6K in Q1 2021. 77 funds tracked by Wall St. Rank hold XPH as of Q4 2021.

Eaton Vance Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2021 after selling out during the quarter.
Eaton Vance Management sold 225 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2021.
Eaton Vance Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2021 and held it in 2 quarters.
Eaton Vance Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $6K in Q1 2021.
77 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2021.

Based on Eaton Vance Management's 13F filing for Q4 2021, filed 14 Feb 2022.